Document is current
Any future updates will be listed below
-
Authors
De Bruycker, A.
Spiessens, A.
Dirix, P.
Koutsouvelis, N.
Semac, I.
Liefhooghe, N.
Gomez-Iturriaga, A.
Everaerts, W.
Otte, F.
Papachristofilou, A.
Scorsetti, M.
Shelan, M.
Siva, S.
Ameye, F.
Guckenberger, M.
Heikkilä, R.
Putora, P. M.
Zapatero, A.
Conde-Moreno, A.
Couñago, F.
Vanhoutte, F.
Goetghebeur, E.
Reynders, D.
Zilli, T.
Ost, P.
-
Funding
Funding for this research was provided by:
Kom op tegen Kanker
Stichting Tegen Kanker
Movember Foundation
- License Information
-
More Information
Article History
Received: 23 March 2020
Accepted: 28 April 2020
First Online: 12 May 2020
Ethics approval and consent to participate
: This research protocol was reviewed and approved by the Ethics committee of the Ghent University Hospital ‘Commissie voor Medische Ethiek, Bimetra Clinics’ (EC/2018/0130), which is the central Institutional Review Board (IRB), and by the local IRB’s at all participating sites before recruitment (see additional file). The study is registered on ExternalRef removed (NCT0356924) and the Swiss National Clinical Trials Portal (SNCTP000002947).Patients will be asked for permission to participate in the trial, and to collect and use their data by means of a signed informed consent before inclusion in the study. This will be obtained from each participant by the responsible radiation oncologist.
: Not applicable.
: PO:Research funding: Merck (Inst), Varian (Inst)Consulting or Advisory Role: Ferring Pharmaceuticals (Inst), Bayer AG (Inst), Janssen (Inst)Travel, Accommodations, Expenses: Ipsen, Ferring PharmaceuticalsAZ:Research funding: Janssen, AstraZenecaAdvisory board: IPSENSpeaker fees: Astellas, Janssen.The other authors declare that they have no competing interests for this trial.
